Split congressional control will result in more drug pricing talk, but don’t expect much action.
Disclosing prices to consumers looks like a fait accompli, although the details are still being debated. Icer, meanwhile, could open the door to biopharma’s early…
Medicare is to review ways to encourage use of non-addictive pain relievers, but Heron Therapeutics will miss out on extension of a special payment provision.
Over industry objections, a Medicare panel endorses patient symptom reporting tools that could lower payments for drugs with a high side-effect burden.
Pharma sector pushes back against a programme that mandates cheaper prices for hospitals serving the poor.
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
As drug prices climb, is it time to ask whether the landmark technology transfer law is a fair deal for US taxpayers?
Regulatory intervention having limited impact on fostering innovation.
Will US right-to-try legislation be a means of giving hope to terminally ill patients, or drug another way for drug regulatory standards to fall?